 Asokumar Buvanendran
Concepts (496)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pain, Postoperative | 41 | 2021 | 306 | 9.170 |
Why?
| | Analgesics, Opioid | 34 | 2021 | 211 | 7.910 |
Why?
| | Pain Management | 23 | 2021 | 139 | 5.700 |
Why?
| | Analgesics | 23 | 2021 | 103 | 4.950 |
Why?
| | Chronic Pain | 26 | 2022 | 102 | 4.460 |
Why?
| | Low Back Pain | 25 | 2021 | 133 | 4.390 |
Why?
| | Pain Measurement | 44 | 2020 | 476 | 3.930 |
Why?
| | Morphine | 21 | 2021 | 80 | 3.700 |
Why?
| | Analgesia | 11 | 2021 | 39 | 3.670 |
Why?
| | Complex Regional Pain Syndromes | 8 | 2020 | 23 | 3.120 |
Why?
| | Arthroplasty, Replacement, Knee | 14 | 2021 | 668 | 2.910 |
Why?
| | Nerve Block | 13 | 2020 | 58 | 2.850 |
Why?
| | Opioid-Related Disorders | 5 | 2021 | 55 | 2.640 |
Why?
| | Anesthetics, Local | 11 | 2016 | 86 | 2.400 |
Why?
| | Disease Models, Animal | 11 | 2020 | 832 | 2.310 |
Why?
| | Anesthesia, Conduction | 12 | 2021 | 26 | 2.220 |
Why?
| | gamma-Aminobutyric Acid | 11 | 2012 | 50 | 2.180 |
Why?
| | Spinal Cord Stimulation | 6 | 2022 | 12 | 2.040 |
Why?
| | Ketamine | 6 | 2019 | 23 | 2.000 |
Why?
| | Dexamethasone | 5 | 2016 | 52 | 1.980 |
Why?
| | Cyclooxygenase Inhibitors | 9 | 2016 | 41 | 1.980 |
Why?
| | Bupivacaine | 5 | 2016 | 55 | 1.920 |
Why?
| | Humans | 117 | 2022 | 31481 | 1.860 |
Why?
| | Pain | 13 | 2021 | 336 | 1.750 |
Why?
| | Arthroplasty, Replacement, Hip | 9 | 2017 | 840 | 1.530 |
Why?
| | Surgical Wound Infection | 4 | 2018 | 106 | 1.490 |
Why?
| | Ketorolac | 4 | 2016 | 16 | 1.400 |
Why?
| | Anti-Inflammatory Agents | 4 | 2016 | 109 | 1.370 |
Why?
| | Female | 67 | 2021 | 18253 | 1.340 |
Why?
| | Male | 75 | 2021 | 17583 | 1.340 |
Why?
| | Motor Activity | 7 | 2017 | 397 | 1.270 |
Why?
| | Injections, Spinal | 7 | 2019 | 54 | 1.250 |
Why?
| | Acute Pain | 4 | 2018 | 17 | 1.240 |
Why?
| | Pain Threshold | 8 | 2021 | 25 | 1.210 |
Why?
| | Cyclooxygenase 2 Inhibitors | 10 | 2010 | 33 | 1.210 |
Why?
| | Middle Aged | 50 | 2021 | 11209 | 1.190 |
Why?
| | Platelet Aggregation Inhibitors | 5 | 2018 | 62 | 1.180 |
Why?
| | Zygapophyseal Joint | 5 | 2020 | 47 | 1.160 |
Why?
| | Animals | 30 | 2020 | 5312 | 1.160 |
Why?
| | Inflammation Mediators | 3 | 2017 | 94 | 1.140 |
Why?
| | Electric Stimulation Therapy | 7 | 2022 | 43 | 1.120 |
Why?
| | Analgesia, Epidural | 7 | 2017 | 61 | 1.110 |
Why?
| | Rats, Sprague-Dawley | 21 | 2018 | 494 | 1.080 |
Why?
| | Spouses | 7 | 2019 | 29 | 1.060 |
Why?
| | Anesthesia, Epidural | 4 | 2015 | 29 | 1.050 |
Why?
| | Analgesia, Patient-Controlled | 5 | 2017 | 28 | 1.050 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2021 | 300 | 1.000 |
Why?
| | Adult | 40 | 2021 | 9779 | 0.990 |
Why?
| | Spine | 4 | 2021 | 125 | 0.970 |
Why?
| | Sciatic Nerve | 5 | 2016 | 32 | 0.950 |
Why?
| | Glucocorticoids | 4 | 2020 | 77 | 0.950 |
Why?
| | Anger | 3 | 2017 | 31 | 0.940 |
Why?
| | Lumbar Vertebrae | 5 | 2021 | 469 | 0.940 |
Why?
| | Clonidine | 6 | 2016 | 31 | 0.940 |
Why?
| | Arthralgia | 4 | 2020 | 120 | 0.920 |
Why?
| | Lactones | 3 | 2007 | 14 | 0.920 |
Why?
| | Cytokines | 4 | 2015 | 364 | 0.900 |
Why?
| | Neuralgia | 3 | 2019 | 14 | 0.890 |
Why?
| | Prospective Studies | 13 | 2021 | 1934 | 0.880 |
Why?
| | Anesthesia, Obstetrical | 2 | 2015 | 12 | 0.870 |
Why?
| | Electrodes, Implanted | 5 | 2018 | 44 | 0.860 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 7 | 2020 | 111 | 0.840 |
Why?
| | Double-Blind Method | 17 | 2021 | 559 | 0.830 |
Why?
| | Abdominal Muscles | 1 | 2020 | 8 | 0.820 |
Why?
| | Antiemetics | 1 | 2020 | 7 | 0.820 |
Why?
| | Metformin | 1 | 2020 | 21 | 0.810 |
Why?
| | Sulfones | 4 | 2010 | 27 | 0.810 |
Why?
| | Time-to-Treatment | 1 | 2020 | 37 | 0.810 |
Why?
| | Central Nervous System | 3 | 2010 | 61 | 0.810 |
Why?
| | Edema | 1 | 2020 | 40 | 0.810 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2019 | 13 | 0.800 |
Why?
| | Aged | 28 | 2021 | 10295 | 0.790 |
Why?
| | Program Evaluation | 1 | 2020 | 153 | 0.790 |
Why?
| | Treatment Outcome | 19 | 2021 | 3910 | 0.770 |
Why?
| | Bariatric Surgery | 1 | 2020 | 43 | 0.770 |
Why?
| | Catastrophization | 5 | 2021 | 15 | 0.760 |
Why?
| | Mice | 7 | 2020 | 1894 | 0.740 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 366 | 0.740 |
Why?
| | Anesthesia | 2 | 2010 | 29 | 0.740 |
Why?
| | Interpersonal Relations | 6 | 2019 | 114 | 0.730 |
Why?
| | Vancomycin | 1 | 2018 | 56 | 0.730 |
Why?
| | Hyperalgesia | 5 | 2017 | 41 | 0.730 |
Why?
| | Amputation | 1 | 2018 | 20 | 0.730 |
Why?
| | Spinal Fusion | 4 | 2021 | 464 | 0.710 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 412 | 0.700 |
Why?
| | Ultrasonography, Interventional | 3 | 2019 | 73 | 0.680 |
Why?
| | Laparotomy | 2 | 2016 | 25 | 0.680 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 4 | 2012 | 35 | 0.680 |
Why?
| | Administration, Intravenous | 2 | 2017 | 34 | 0.670 |
Why?
| | Societies, Medical | 7 | 2020 | 209 | 0.670 |
Why?
| | Cyclohexanecarboxylic Acids | 4 | 2012 | 16 | 0.660 |
Why?
| | Amines | 4 | 2012 | 17 | 0.660 |
Why?
| | Buprenorphine | 1 | 2016 | 5 | 0.650 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 548 | 0.650 |
Why?
| | Anticoagulants | 6 | 2018 | 151 | 0.630 |
Why?
| | Equipment Failure | 1 | 2016 | 50 | 0.630 |
Why?
| | Epidural Space | 3 | 2015 | 22 | 0.620 |
Why?
| | International Cooperation | 1 | 2015 | 38 | 0.610 |
Why?
| | Cervical Vertebrae | 3 | 2016 | 343 | 0.610 |
Why?
| | Joints | 1 | 2016 | 101 | 0.600 |
Why?
| | Spinal Cord | 5 | 2012 | 99 | 0.600 |
Why?
| | Health Surveys | 1 | 2015 | 102 | 0.590 |
Why?
| | Platelet Function Tests | 1 | 2015 | 5 | 0.590 |
Why?
| | Ticlopidine | 1 | 2015 | 14 | 0.580 |
Why?
| | Random Allocation | 4 | 2020 | 164 | 0.580 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2014 | 8 | 0.580 |
Why?
| | Medication Errors | 1 | 2015 | 20 | 0.580 |
Why?
| | Pregnancy Complications | 1 | 2015 | 57 | 0.570 |
Why?
| | Steroids | 1 | 2014 | 30 | 0.570 |
Why?
| | Infusion Pumps | 1 | 2014 | 16 | 0.560 |
Why?
| | Dinoprostone | 4 | 2007 | 28 | 0.560 |
Why?
| | General Surgery | 1 | 2015 | 61 | 0.550 |
Why?
| | Consensus | 8 | 2022 | 106 | 0.550 |
Why?
| | Patient Satisfaction | 3 | 2017 | 315 | 0.540 |
Why?
| | Hematoma, Epidural, Spinal | 1 | 2014 | 4 | 0.540 |
Why?
| | Time Factors | 11 | 2018 | 1902 | 0.540 |
Why?
| | Infection Control | 1 | 2015 | 171 | 0.540 |
Why?
| | Young Adult | 10 | 2018 | 2277 | 0.540 |
Why?
| | Practice Guidelines as Topic | 5 | 2020 | 389 | 0.540 |
Why?
| | Rats | 16 | 2018 | 966 | 0.530 |
Why?
| | Models, Animal | 2 | 2016 | 149 | 0.510 |
Why?
| | Fentanyl | 2 | 2003 | 23 | 0.510 |
Why?
| | Severity of Illness Index | 3 | 2015 | 1240 | 0.500 |
Why?
| | Aspirin | 1 | 2014 | 90 | 0.500 |
Why?
| | Naloxone | 6 | 2019 | 12 | 0.500 |
Why?
| | Magnesium | 2 | 2003 | 52 | 0.500 |
Why?
| | Length of Stay | 4 | 2021 | 377 | 0.480 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2011 | 15 | 0.470 |
Why?
| | Substance P | 1 | 2011 | 19 | 0.470 |
Why?
| | Catheter Ablation | 3 | 2018 | 76 | 0.470 |
Why?
| | Norepinephrine | 1 | 2011 | 34 | 0.470 |
Why?
| | Phantom Limb | 2 | 2008 | 4 | 0.470 |
Why?
| | Glutamic Acid | 1 | 2011 | 36 | 0.470 |
Why?
| | Chronic Disease | 7 | 2010 | 544 | 0.470 |
Why?
| | Isoenzymes | 4 | 2004 | 63 | 0.460 |
Why?
| | Drug Administration Schedule | 6 | 2018 | 257 | 0.460 |
Why?
| | Hypoglycemic Agents | 3 | 2020 | 76 | 0.450 |
Why?
| | Combined Modality Therapy | 6 | 2018 | 456 | 0.450 |
Why?
| | Evidence-Based Medicine | 6 | 2018 | 239 | 0.450 |
Why?
| | Blood Patch, Epidural | 2 | 2008 | 9 | 0.440 |
Why?
| | Positron-Emission Tomography | 2 | 2010 | 95 | 0.440 |
Why?
| | Cohort Studies | 5 | 2021 | 2014 | 0.440 |
Why?
| | Postoperative Complications | 3 | 2021 | 1083 | 0.440 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2010 | 13 | 0.440 |
Why?
| | Injections | 5 | 2020 | 59 | 0.440 |
Why?
| | Neutrophils | 2 | 2016 | 133 | 0.410 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2011 | 81 | 0.410 |
Why?
| | Denervation | 3 | 2020 | 23 | 0.400 |
Why?
| | Behavior, Animal | 5 | 2016 | 113 | 0.400 |
Why?
| | Hostility | 3 | 2018 | 21 | 0.400 |
Why?
| | Cross-Over Studies | 7 | 2018 | 82 | 0.400 |
Why?
| | United States | 12 | 2021 | 2539 | 0.400 |
Why?
| | Diabetes Mellitus, Experimental | 4 | 2015 | 35 | 0.400 |
Why?
| | Wound Healing | 1 | 2010 | 175 | 0.390 |
Why?
| | Drug Delivery Systems | 2 | 2019 | 40 | 0.390 |
Why?
| | Hip Joint | 3 | 2012 | 339 | 0.390 |
Why?
| | Hematoma, Subdural, Intracranial | 1 | 2008 | 3 | 0.380 |
Why?
| | Opioid Peptides | 4 | 2020 | 6 | 0.380 |
Why?
| | Subdural Effusion | 1 | 2008 | 7 | 0.380 |
Why?
| | Brain Mapping | 1 | 2010 | 199 | 0.380 |
Why?
| | Brain | 2 | 2010 | 1655 | 0.380 |
Why?
| | Memantine | 1 | 2008 | 12 | 0.370 |
Why?
| | Chicago | 4 | 2015 | 955 | 0.370 |
Why?
| | Pilot Projects | 3 | 2020 | 455 | 0.370 |
Why?
| | Physicians, Family | 1 | 2008 | 7 | 0.360 |
Why?
| | Specialization | 1 | 2008 | 21 | 0.350 |
Why?
| | Administration, Oral | 3 | 2018 | 164 | 0.350 |
Why?
| | Sleep | 3 | 2019 | 357 | 0.350 |
Why?
| | Cyclooxygenase 2 | 6 | 2008 | 33 | 0.340 |
Why?
| | Diclofenac | 1 | 2007 | 4 | 0.340 |
Why?
| | Decompression, Surgical | 2 | 2021 | 146 | 0.340 |
Why?
| | Ossification, Heterotopic | 1 | 2007 | 40 | 0.340 |
Why?
| | Neoplasms | 1 | 2010 | 280 | 0.330 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 351 | 0.330 |
Why?
| | Referral and Consultation | 1 | 2008 | 99 | 0.330 |
Why?
| | Drug Combinations | 2 | 2016 | 88 | 0.330 |
Why?
| | Narcotic Antagonists | 5 | 2017 | 13 | 0.320 |
Why?
| | Preoperative Care | 1 | 2007 | 146 | 0.320 |
Why?
| | Acetaminophen | 3 | 2012 | 20 | 0.310 |
Why?
| | Interleukins | 1 | 2006 | 42 | 0.310 |
Why?
| | Pregnancy | 4 | 2015 | 457 | 0.300 |
Why?
| | Adrenal Cortex Hormones | 2 | 2018 | 100 | 0.300 |
Why?
| | Risk Factors | 6 | 2018 | 2664 | 0.300 |
Why?
| | Orthopedics | 1 | 2007 | 133 | 0.290 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 5 | 2006 | 29 | 0.290 |
Why?
| | Thoracotomy | 1 | 2004 | 34 | 0.290 |
Why?
| | Retrospective Studies | 7 | 2021 | 3591 | 0.280 |
Why?
| | Adaptation, Psychological | 4 | 2018 | 176 | 0.280 |
Why?
| | Athletic Injuries | 1 | 2006 | 182 | 0.280 |
Why?
| | Superior Vena Cava Syndrome | 1 | 2004 | 8 | 0.280 |
Why?
| | Perioperative Care | 3 | 2018 | 75 | 0.260 |
Why?
| | Postoperative Period | 5 | 2019 | 295 | 0.260 |
Why?
| | Adrenergic alpha-Agonists | 3 | 2009 | 18 | 0.260 |
Why?
| | Acute Kidney Injury | 1 | 2004 | 64 | 0.260 |
Why?
| | Drug Therapy, Combination | 3 | 2016 | 265 | 0.260 |
Why?
| | Injections, Intra-Articular | 4 | 2020 | 81 | 0.250 |
Why?
| | Catheterization | 2 | 2015 | 62 | 0.250 |
Why?
| | Insulin | 2 | 2015 | 116 | 0.250 |
Why?
| | Exploratory Behavior | 2 | 2016 | 23 | 0.250 |
Why?
| | Affect | 3 | 2019 | 72 | 0.250 |
Why?
| | Analgesia, Obstetrical | 1 | 2002 | 26 | 0.240 |
Why?
| | Self Report | 3 | 2019 | 225 | 0.240 |
Why?
| | Aged, 80 and over | 5 | 2020 | 5234 | 0.230 |
Why?
| | Lidocaine | 4 | 2012 | 44 | 0.230 |
Why?
| | Headache Disorders | 2 | 2014 | 4 | 0.230 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 2 | 2012 | 2 | 0.230 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2020 | 375 | 0.230 |
Why?
| | Knee Joint | 3 | 2018 | 775 | 0.220 |
Why?
| | Ontario | 1 | 2021 | 18 | 0.220 |
Why?
| | Telemedicine | 2 | 2020 | 99 | 0.220 |
Why?
| | Radiography | 3 | 2015 | 717 | 0.220 |
Why?
| | Cesarean Section | 2 | 2015 | 33 | 0.210 |
Why?
| | Adolescent | 4 | 2018 | 2667 | 0.210 |
Why?
| | Anticonvulsants | 2 | 2012 | 110 | 0.210 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 2 | 2010 | 16 | 0.210 |
Why?
| | Tibial Fractures | 1 | 2020 | 13 | 0.210 |
Why?
| | Activities of Daily Living | 4 | 2018 | 495 | 0.210 |
Why?
| | Up-Regulation | 5 | 2008 | 220 | 0.200 |
Why?
| | Anesthesiology | 1 | 2020 | 28 | 0.200 |
Why?
| | Off-Label Use | 1 | 2019 | 6 | 0.200 |
Why?
| | Illness Behavior | 1 | 2019 | 3 | 0.200 |
Why?
| | Endocannabinoids | 1 | 2019 | 3 | 0.200 |
Why?
| | Uncertainty | 1 | 2019 | 7 | 0.200 |
Why?
| | Physician's Role | 1 | 2019 | 22 | 0.190 |
Why?
| | Oxycodone | 1 | 2019 | 6 | 0.190 |
Why?
| | Hospitals | 1 | 2020 | 142 | 0.190 |
Why?
| | Musculoskeletal Pain | 1 | 2019 | 19 | 0.190 |
Why?
| | Physicians | 1 | 2021 | 120 | 0.190 |
Why?
| | Social Perception | 1 | 2019 | 23 | 0.190 |
Why?
| | Rodentia | 1 | 2018 | 7 | 0.190 |
Why?
| | Drug Prescriptions | 1 | 2019 | 37 | 0.190 |
Why?
| | Incidence | 2 | 2015 | 829 | 0.190 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 378 | 0.190 |
Why?
| | Anesthesia, Spinal | 2 | 2015 | 19 | 0.190 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2009 | 22 | 0.180 |
Why?
| | Coronavirus Infections | 1 | 2020 | 97 | 0.180 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 102 | 0.180 |
Why?
| | Betamethasone | 1 | 2018 | 3 | 0.180 |
Why?
| | Triamcinolone Acetonide | 1 | 2018 | 5 | 0.180 |
Why?
| | Ischemia | 2 | 2017 | 35 | 0.180 |
Why?
| | Sacroiliac Joint | 1 | 2018 | 6 | 0.180 |
Why?
| | Marriage | 1 | 2018 | 9 | 0.180 |
Why?
| | Affective Symptoms | 1 | 2018 | 12 | 0.180 |
Why?
| | Spinal Puncture | 2 | 2011 | 23 | 0.180 |
Why?
| | Laparoscopy | 1 | 2020 | 190 | 0.180 |
Why?
| | Methylprednisolone | 1 | 2018 | 26 | 0.180 |
Why?
| | Peripheral Nervous System Diseases | 2 | 2009 | 38 | 0.170 |
Why?
| | Arousal | 2 | 2015 | 56 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2012 | 512 | 0.170 |
Why?
| | Triage | 2 | 2020 | 30 | 0.170 |
Why?
| | Amides | 2 | 2010 | 21 | 0.170 |
Why?
| | Classification | 1 | 2017 | 4 | 0.170 |
Why?
| | Medical History Taking | 1 | 2017 | 26 | 0.170 |
Why?
| | Ganglia, Spinal | 1 | 2017 | 47 | 0.170 |
Why?
| | beta-Endorphin | 1 | 2017 | 1 | 0.170 |
Why?
| | Symptom Assessment | 1 | 2017 | 24 | 0.170 |
Why?
| | Knee | 1 | 2017 | 46 | 0.170 |
Why?
| | Mood Disorders | 1 | 2017 | 34 | 0.170 |
Why?
| | Patient Selection | 3 | 2014 | 264 | 0.170 |
Why?
| | Wound Closure Techniques | 1 | 2016 | 10 | 0.170 |
Why?
| | Injections, Epidural | 2 | 2015 | 16 | 0.170 |
Why?
| | Anticipation, Psychological | 1 | 2016 | 8 | 0.160 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 7 | 0.160 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 230 | 0.160 |
Why?
| | Neuralgia, Postherpetic | 1 | 2015 | 2 | 0.160 |
Why?
| | Herpes Zoster | 1 | 2015 | 4 | 0.150 |
Why?
| | Reproducibility of Results | 3 | 2014 | 886 | 0.150 |
Why?
| | Pseudomonas Infections | 1 | 2016 | 63 | 0.150 |
Why?
| | Oxygen | 1 | 2016 | 94 | 0.150 |
Why?
| | Research Design | 1 | 2018 | 238 | 0.150 |
Why?
| | Pseudomonas aeruginosa | 1 | 2016 | 85 | 0.150 |
Why?
| | Diagnostic Self Evaluation | 1 | 2015 | 16 | 0.150 |
Why?
| | Ibuprofen | 1 | 2015 | 12 | 0.150 |
Why?
| | Sex Distribution | 1 | 2015 | 89 | 0.150 |
Why?
| | Catheters | 1 | 2015 | 8 | 0.150 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2015 | 33 | 0.150 |
Why?
| | Age Distribution | 1 | 2015 | 110 | 0.150 |
Why?
| | Health Care Surveys | 1 | 2015 | 77 | 0.150 |
Why?
| | Joint Capsule | 1 | 2015 | 45 | 0.140 |
Why?
| | Autoantibodies | 1 | 2015 | 119 | 0.140 |
Why?
| | Infusions, Intravenous | 4 | 2018 | 89 | 0.140 |
Why?
| | Muscle Spasticity | 1 | 2014 | 15 | 0.140 |
Why?
| | Social Behavior | 1 | 2015 | 108 | 0.140 |
Why?
| | Endpoint Determination | 1 | 2014 | 31 | 0.140 |
Why?
| | Migraine Disorders | 1 | 2014 | 22 | 0.140 |
Why?
| | Algorithms | 1 | 2017 | 412 | 0.140 |
Why?
| | Orthopedic Procedures | 1 | 2018 | 322 | 0.140 |
Why?
| | Pain Clinics | 1 | 2014 | 6 | 0.140 |
Why?
| | Blood Glucose | 1 | 2015 | 137 | 0.140 |
Why?
| | Anesthesia, General | 1 | 2014 | 33 | 0.130 |
Why?
| | Patient Safety | 1 | 2014 | 53 | 0.130 |
Why?
| | Recovery of Function | 2 | 2017 | 309 | 0.130 |
Why?
| | Cross-Sectional Studies | 5 | 2019 | 986 | 0.130 |
Why?
| | Range of Motion, Articular | 2 | 2009 | 703 | 0.130 |
Why?
| | Regression Analysis | 3 | 2019 | 319 | 0.130 |
Why?
| | Nervous System Diseases | 1 | 2015 | 145 | 0.130 |
Why?
| | Quality of Life | 1 | 2018 | 663 | 0.130 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 176 | 0.120 |
Why?
| | Skin | 2 | 2010 | 136 | 0.120 |
Why?
| | Longitudinal Studies | 1 | 2017 | 1452 | 0.120 |
Why?
| | Phenols | 1 | 2012 | 10 | 0.120 |
Why?
| | Capsaicin | 1 | 2012 | 12 | 0.120 |
Why?
| | Membrane Proteins | 2 | 2004 | 230 | 0.120 |
Why?
| | Perioperative Period | 1 | 2011 | 13 | 0.120 |
Why?
| | Osteoarthritis, Spine | 1 | 2011 | 7 | 0.120 |
Why?
| | Hospitalization | 1 | 2015 | 359 | 0.120 |
Why?
| | Exercise | 3 | 2021 | 454 | 0.110 |
Why?
| | Back Pain | 1 | 2011 | 49 | 0.110 |
Why?
| | International Normalized Ratio | 1 | 2011 | 32 | 0.110 |
Why?
| | Interleukin-6 | 2 | 2015 | 120 | 0.110 |
Why?
| | Intracranial Hypotension | 2 | 2008 | 7 | 0.110 |
Why?
| | Biological Availability | 1 | 2010 | 26 | 0.110 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2010 | 43 | 0.110 |
Why?
| | Blood Loss, Surgical | 2 | 2018 | 71 | 0.110 |
Why?
| | Radioisotopes | 1 | 2010 | 16 | 0.110 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2011 | 45 | 0.110 |
Why?
| | Warfarin | 1 | 2011 | 60 | 0.110 |
Why?
| | Peripheral Nerves | 2 | 2014 | 19 | 0.110 |
Why?
| | Diabetic Neuropathies | 1 | 2010 | 15 | 0.110 |
Why?
| | Preoperative Period | 1 | 2010 | 73 | 0.110 |
Why?
| | Physical Stimulation | 2 | 2013 | 17 | 0.110 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2010 | 39 | 0.100 |
Why?
| | Epinephrine | 4 | 2012 | 30 | 0.100 |
Why?
| | Intervertebral Disc Degeneration | 1 | 2011 | 117 | 0.100 |
Why?
| | Neostigmine | 2 | 2007 | 6 | 0.100 |
Why?
| | Interleukin-18 Receptor alpha Subunit | 1 | 2009 | 2 | 0.100 |
Why?
| | Interleukin-18 Receptor beta Subunit | 1 | 2009 | 2 | 0.100 |
Why?
| | Chemokine CCL20 | 1 | 2009 | 2 | 0.100 |
Why?
| | Macrophage Migration-Inhibitory Factors | 1 | 2009 | 3 | 0.100 |
Why?
| | Pyridines | 1 | 2010 | 50 | 0.100 |
Why?
| | Area Under Curve | 2 | 2010 | 79 | 0.100 |
Why?
| | Databases as Topic | 1 | 2009 | 22 | 0.100 |
Why?
| | Muscle, Skeletal | 2 | 2015 | 385 | 0.100 |
Why?
| | Drug Synergism | 3 | 2004 | 67 | 0.100 |
Why?
| | Psychometrics | 1 | 2010 | 287 | 0.100 |
Why?
| | Posterior Horn Cells | 1 | 2008 | 5 | 0.090 |
Why?
| | Postoperative Nausea and Vomiting | 2 | 2006 | 17 | 0.090 |
Why?
| | Interprofessional Relations | 1 | 2008 | 43 | 0.090 |
Why?
| | Pain, Intractable | 1 | 2007 | 16 | 0.090 |
Why?
| | Treatment Failure | 1 | 2008 | 187 | 0.090 |
Why?
| | Recurrence | 1 | 2008 | 389 | 0.090 |
Why?
| | Terrorism | 1 | 2007 | 15 | 0.090 |
Why?
| | Quality of Health Care | 1 | 2009 | 141 | 0.090 |
Why?
| | Drug Interactions | 1 | 2007 | 70 | 0.080 |
Why?
| | Microglia | 1 | 2008 | 131 | 0.080 |
Why?
| | United States Food and Drug Administration | 2 | 2019 | 75 | 0.080 |
Why?
| | Neuronal Plasticity | 1 | 2007 | 50 | 0.080 |
Why?
| | Europe | 2 | 2017 | 88 | 0.080 |
Why?
| | Sulfonamides | 1 | 2006 | 64 | 0.080 |
Why?
| | Intraoperative Period | 1 | 2006 | 39 | 0.080 |
Why?
| | Indans | 2 | 2004 | 12 | 0.080 |
Why?
| | Interleukin-8 | 1 | 2006 | 38 | 0.080 |
Why?
| | Depression | 3 | 2019 | 516 | 0.080 |
Why?
| | Cartilage, Articular | 1 | 2011 | 586 | 0.080 |
Why?
| | Interleukin-1 | 1 | 2006 | 91 | 0.080 |
Why?
| | Pyrazoles | 1 | 2006 | 55 | 0.080 |
Why?
| | Arachnoiditis | 1 | 2005 | 4 | 0.080 |
Why?
| | Electronic Health Records | 2 | 2018 | 82 | 0.080 |
Why?
| | Cauda Equina | 1 | 2005 | 7 | 0.080 |
Why?
| | Depressive Disorder | 1 | 2007 | 212 | 0.080 |
Why?
| | Reoperation | 1 | 2010 | 938 | 0.070 |
Why?
| | Vascular Surgical Procedures | 1 | 2006 | 56 | 0.070 |
Why?
| | Arthroplasty, Replacement | 1 | 2007 | 147 | 0.070 |
Why?
| | Peripheral Nerve Injuries | 2 | 2015 | 18 | 0.070 |
Why?
| | Tissue Fixation | 1 | 2004 | 11 | 0.070 |
Why?
| | Cold Temperature | 1 | 2004 | 39 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2008 | 2028 | 0.070 |
Why?
| | Ribs | 1 | 2004 | 19 | 0.070 |
Why?
| | Transcranial Magnetic Stimulation | 2 | 2014 | 18 | 0.070 |
Why?
| | Sex Factors | 3 | 2014 | 542 | 0.070 |
Why?
| | Herb-Drug Interactions | 1 | 2004 | 1 | 0.070 |
Why?
| | Nonprescription Drugs | 1 | 2004 | 2 | 0.070 |
Why?
| | Plant Preparations | 1 | 2004 | 9 | 0.070 |
Why?
| | Mediastinal Neoplasms | 1 | 2004 | 15 | 0.070 |
Why?
| | Weight Gain | 1 | 2004 | 70 | 0.070 |
Why?
| | Dyssomnias | 1 | 2003 | 8 | 0.070 |
Why?
| | Neurosurgery | 2 | 2014 | 49 | 0.070 |
Why?
| | Social Support | 2 | 2015 | 224 | 0.060 |
Why?
| | Fetal Monitoring | 1 | 2002 | 4 | 0.060 |
Why?
| | Heart Rate, Fetal | 1 | 2002 | 5 | 0.060 |
Why?
| | Pruritus | 1 | 2002 | 15 | 0.060 |
Why?
| | Risk Assessment | 1 | 2006 | 806 | 0.060 |
Why?
| | Intracranial Pressure | 1 | 2002 | 24 | 0.060 |
Why?
| | Ion Channels | 1 | 2004 | 232 | 0.060 |
Why?
| | Heart Rate | 1 | 2002 | 161 | 0.060 |
Why?
| | Trigger Points | 1 | 2020 | 1 | 0.060 |
Why?
| | United States Department of Veterans Affairs | 1 | 2020 | 10 | 0.050 |
Why?
| | Appointments and Schedules | 1 | 2020 | 15 | 0.050 |
Why?
| | Blood Pressure | 1 | 2002 | 260 | 0.050 |
Why?
| | Military Medicine | 1 | 2020 | 15 | 0.050 |
Why?
| | Disinfection | 1 | 2020 | 13 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 38 | 0.050 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2020 | 25 | 0.050 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2020 | 39 | 0.050 |
Why?
| | Public Health | 1 | 2020 | 66 | 0.050 |
Why?
| | Radio Waves | 1 | 2020 | 9 | 0.050 |
Why?
| | Infusion Pumps, Implantable | 1 | 2019 | 13 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2020 | 113 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2004 | 442 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2010 | 467 | 0.050 |
Why?
| | Mass Screening | 1 | 2020 | 199 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2004 | 891 | 0.050 |
Why?
| | Pandemics | 1 | 2020 | 203 | 0.050 |
Why?
| | Forecasting | 1 | 2019 | 134 | 0.050 |
Why?
| | Medical Records | 1 | 2018 | 40 | 0.050 |
Why?
| | Disability Evaluation | 2 | 2014 | 332 | 0.040 |
Why?
| | Postoperative Hemorrhage | 1 | 2018 | 31 | 0.040 |
Why?
| | Thigh | 1 | 2017 | 36 | 0.040 |
Why?
| | Anxiety | 1 | 2019 | 162 | 0.040 |
Why?
| | Public-Private Sector Partnerships | 1 | 2017 | 5 | 0.040 |
Why?
| | African Americans | 1 | 2005 | 818 | 0.040 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 53 | 0.040 |
Why?
| | Administration, Intravesical | 1 | 2017 | 4 | 0.040 |
Why?
| | Pain Perception | 1 | 2017 | 7 | 0.040 |
Why?
| | Hot Temperature | 1 | 2017 | 26 | 0.040 |
Why?
| | Rest | 1 | 2017 | 33 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2015 | 5 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 30 | 0.040 |
Why?
| | Computers, Handheld | 1 | 2015 | 14 | 0.040 |
Why?
| | Streptozocin | 1 | 2015 | 7 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2017 | 128 | 0.040 |
Why?
| | Anatomic Landmarks | 1 | 2015 | 8 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2017 | 386 | 0.040 |
Why?
| | Empathy | 1 | 2015 | 43 | 0.040 |
Why?
| | North America | 1 | 2015 | 44 | 0.040 |
Why?
| | Dissection | 1 | 2015 | 29 | 0.040 |
Why?
| | Flatulence | 1 | 2015 | 1 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2015 | 120 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2015 | 71 | 0.040 |
Why?
| | Internationality | 1 | 2015 | 26 | 0.040 |
Why?
| | Models, Psychological | 1 | 2015 | 89 | 0.040 |
Why?
| | Perception | 1 | 2015 | 92 | 0.040 |
Why?
| | Walking | 1 | 2017 | 249 | 0.040 |
Why?
| | Optogenetics | 1 | 2014 | 1 | 0.040 |
Why?
| | Facial Pain | 1 | 2014 | 7 | 0.040 |
Why?
| | Equipment Safety | 1 | 2014 | 13 | 0.040 |
Why?
| | Registries | 1 | 2016 | 214 | 0.040 |
Why?
| | Angina Pectoris | 1 | 2014 | 18 | 0.040 |
Why?
| | Neuronavigation | 1 | 2014 | 9 | 0.040 |
Why?
| | Vagus Nerve Stimulation | 1 | 2014 | 8 | 0.040 |
Why?
| | Wound Infection | 1 | 2014 | 13 | 0.040 |
Why?
| | Hematoma | 1 | 2014 | 24 | 0.030 |
Why?
| | Headache | 1 | 2014 | 52 | 0.030 |
Why?
| | Checklist | 1 | 2014 | 42 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2014 | 54 | 0.030 |
Why?
| | Spinal Cord Injuries | 1 | 2014 | 43 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 59 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 153 | 0.030 |
Why?
| | Diskectomy | 1 | 2016 | 181 | 0.030 |
Why?
| | Deep Brain Stimulation | 1 | 2014 | 76 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 156 | 0.030 |
Why?
| | Vasoconstrictor Agents | 1 | 2012 | 31 | 0.030 |
Why?
| | Implants, Experimental | 1 | 2012 | 29 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2014 | 192 | 0.030 |
Why?
| | Mental Disorders | 1 | 2014 | 206 | 0.030 |
Why?
| | Catheters, Indwelling | 1 | 2011 | 30 | 0.030 |
Why?
| | Adrenergic Agonists | 1 | 2010 | 5 | 0.030 |
Why?
| | Sensation | 1 | 2010 | 18 | 0.030 |
Why?
| | Prevalence | 1 | 2012 | 544 | 0.030 |
Why?
| | Absorption | 1 | 2010 | 3 | 0.030 |
Why?
| | Prostaglandins E | 1 | 2010 | 5 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 637 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 21 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 22 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2010 | 50 | 0.030 |
Why?
| | Nerve Degeneration | 1 | 2010 | 57 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 410 | 0.030 |
Why?
| | Information Management | 1 | 2009 | 1 | 0.020 |
Why?
| | Program Development | 1 | 2009 | 76 | 0.020 |
Why?
| | Quality Indicators, Health Care | 1 | 2009 | 43 | 0.020 |
Why?
| | Prognosis | 1 | 2012 | 1028 | 0.020 |
Why?
| | Data Collection | 1 | 2009 | 120 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2010 | 580 | 0.020 |
Why?
| | Databases, Factual | 1 | 2010 | 391 | 0.020 |
Why?
| | Internet | 1 | 2009 | 103 | 0.020 |
Why?
| | September 11 Terrorist Attacks | 1 | 2007 | 11 | 0.020 |
Why?
| | Causality | 1 | 2007 | 58 | 0.020 |
Why?
| | Isoflurane | 1 | 2006 | 10 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2008 | 494 | 0.020 |
Why?
| | Thoracic Surgical Procedures | 1 | 2006 | 12 | 0.020 |
Why?
| | Anxiety Disorders | 1 | 2007 | 176 | 0.020 |
Why?
| | Lower Extremity | 1 | 2006 | 37 | 0.020 |
Why?
| | Vocalization, Animal | 1 | 2005 | 6 | 0.020 |
Why?
| | Tissue Adhesions | 1 | 2005 | 10 | 0.020 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2004 | 3 | 0.020 |
Why?
| | Lumbosacral Region | 1 | 2005 | 71 | 0.020 |
Why?
| | Colforsin | 1 | 2004 | 13 | 0.020 |
Why?
| | Pyrimidines | 1 | 2004 | 31 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2004 | 248 | 0.020 |
Why?
| | Acetates | 1 | 2003 | 26 | 0.020 |
Why?
| | Cholinesterase Inhibitors | 1 | 2003 | 20 | 0.020 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2007 | 226 | 0.020 |
Why?
| | Foot | 1 | 2003 | 35 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2002 | 41 | 0.020 |
Why?
| | Cisterna Magna | 1 | 2002 | 6 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2007 | 1300 | 0.010 |
Why?
|
|
Buvanendran's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|